Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $130 from $78 and keeps a Buy rating on the shares. The firm is pounding the table on Corcept Therapeutics because of the strong likelihood of relacorilant approval in Cushing’s 2025, they believe Phase III ROSELLA data will impress in 1Q25, and CATALYST data will continue to drive Cushing’s franchise
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio